Webcast Transcript
Anthrax: What Every Clinician Should Know, Part 2
(November 1, 2001)
(View the webcast on the University of North Carolina School of Public Health site.)
Segment 9 of 10
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
<< previous | contents | next >>
Dr. Caine:
We are going to
open this up to more questions from our audience. We will start.
Dr. Valentine Burroughs:
Thank you, Dr. Caine.
I’m Dr. Valentine Burroughs, Chairman of the Health Policy Committee
for the National Medical Association. My question to you is, what
should a clinician do if he or she suspects that a patient has anthrax,
and where can they be tested?
Dr. Caine:
I think the key
thing is, is that it’s really important to confirm the diagnosis
by obtaining a laboratory diagnosis or making appropriate laboratory
specimens. Depending on what form of illness you have, whether it’s
inhalational or cutaneous or gastrointestinal, you want to take
those particular specimens. And also I really would advise, consult
an infectious disease specialist if you have it available or consult
your local health department officials. They should be well qualified
in order to provide the additional information for you. Also I think
in terms of exposure circumstances, these are really important factors
as you make your decisions in terms of prophylaxis and so if you
need additional information, remember: regardless of what your laboratory
test shows, if you can document some definite exposure in regard
to anthrax, please place them on antimicrobial prophylaxis antibiotics.
Dr. Fernando Daniels III:
Hi, I’m Dr. Fernando
Daniels III, the Section Chair for Emergency Medicine at the NMA.
Dr. Khan, is the CDC specifically recommending influenza vaccine
for the postal workers?
Dr. Khan:
Excellent question,
especially as we come up on influenza season in the United States.
Dr. Caine has already made the point that we should maybe use the
term “nonspecific febrile illness” for anthrax instead of flu because
there is no coryza and rhinitis. Back to the vaccine issue, ACIP
has a set of recommendations of who to be vaccinated—the elderly,
the immunocompromised, people in high-risk groups. However, the
recommendations are quite permissive in that any other individuals
or groups of individuals who require vaccinations should be vaccinated.
Postal workers would fall into those groups. Influenza among postal
workers would potentially disrupt services and it’s very appropriate
for postal workers to be vaccinated against influenza. However,
we should be quite clear that flu vaccine will not prevent anthrax.
Dr. Daniels:
My second question
is to Dr. Walks. How are the healthcare systems going to cope with
the influx of patients with flu or anthrax symptoms this year?
Dr. Walks:
Well, Dr. Daniels,
I think it’s really a follow on through to Dr. Khan’s answer. I
think it is important for us to first of all get our hospitals all
talking together. Here in Washington, D.C., we have a 10 a.m. conference
call. The hospital association put that together, doctors, hospitals,
regional health officers all talk to each other every day. As we
approach flu season, the two questions are, are we all clear what
to do when our emergency rooms get clogged? How are we going to
respond to that? I think we are going to give a lot of people their
flu shots. I think that’s job one, but then job two is to make sure
we understand, as our emergency rooms get crowded, what is our response
going to be? We don’t have a test in a healthy person for anthrax.
I think that is clear. So that needs to get out to the medical community
and into the public. Don’t rush to your ER to ask for your anthrax
test; we don’t have one. I think that sort of public education campaign
can avoid a lot of clogged ERs.
Dr. Albert Morris:
I’m Dr. Albert Morris,
Chairman of the Environmental Task Force for the National Medical
Association, and my question is for Dr. Satcher. There have been
some influenza vaccine delays this year. How will that affect our
flu season?
Dr. Satcher:
Well, there will
be a slight delay, but not as much as last year. We have delivered
all 79 million plus doses that we expect to have for influenza vaccine.
Forty-four million were delivered by the end of October, and we
believe the rest will be delivered by the middle of November. So
we feel very good about the availability of the vaccine. Now we
are assuming the need to be around 79 million dosages. Getting back
to Dr. Walks’s point earlier, we don’t believe that the vaccine
should be used to help people avoid confusing symptoms with the
flu; you’ve heard what the symptoms are and we’re not using it that
way. We believe that we should target first people who are over
65 years of age or people who have chronic illnesses or people who
work with those people—and healthcare workers especially, because
they can both get influenza from patients, but they can also give
it if they are working around patients who are elderly or at high
risk. So we think we ought to target the high-risk people first
and then certainly after November 15th people between
the ages of 50 and 64 are now recommended by the CDC as lower risk,
but somebody who should get it. Remember, last year we had 100,000
hospitalizations for influenza and we had 20,000 deaths. So it is
very important to be aggressive in immunizing older people and people
with chronic diseases.
Dr. Marinelle Payton:
Hi, I’m Marinelle
Payton, Chair of the Department of Public Health, School of Allied
Health Sciences, Jackson State University. My question is for Dr.
Caine. Dr. Caine, given the susceptible populations—children versus
elderly, risk versus benefits—are there contraindications in the
use of either cipro, doxycycline, or other types of antibiotics?
Dr. Caine:
In the past, at
least for cipro and even the tetracyclines, especially in children
have had adverse health outcomes. If we look at cipro it causes
impacts on the metastasis of the bone formation as young children
are growing and it affects their metastasal plate and so it has
been contraindicated in children. Also we have seen staining of
teeth for the tetracyclines or doxycyclines in children. Also their
bones are also dose-related as well. We have certain contraindications
for doxycycline in pregnant women, and especially—sometimes they
are allowed to be used before six months of gestation but I would
never recommend that without making sure that you are talking to
the family practitioner, OB or gyn, or the midwife who is taking
care of these pregnant mothers and if we can have the susceptibility
studies available we can also place them on amoxicillin in those
instances if the penicillin susceptibility has been confirmed.
Dr. Morris:
My question again
is for Dr. Satcher. Some of our patients are concerned that the
treatment of response protocols have changed as this outbreak has
progressed. Can you help us understand why this is happening?
Dr. Satcher:
Yes, as we mentioned
before I think this is an evolving experience that we are having
here. Our first concern I think was understandable and that is,
we didn’t know if this organism would be resistant to say penicillin
or doxycycline or agents that have been around for a long time so
therefore you would expect it to be more resistant. Ciprofloxacin,
on the other hand, has been around about—what, 15 years?—not a lot
of resistance to ciprofloxacin. You don’t want to take any chance
with inhalation anthrax as you’ve heard from Dr. Caine and others.
So you go with the big gun at the beginning until you find out for
certain that this organism is sensitive to other agents like penicillin
and doxycycline. So what we have done is we’ve determined now after
all of this experience that all of these different outbreaks, if
you will, have been with organisms that are sensitive to doxycycline.
As you have heard, there is some concern about penicillin, especially
if you are actually treating inhalation anthrax, and the possibility
that even if there is not resistance at first, because of penicillinase
development you could get resistance later. So in the exposure mode
you can use penicillin, amoxicillin, but you want to make sure that
if you are treating somebody with inhalation anthrax you go with
something that is certain, so you are going to combine ciprofloxacin
or doxycycline with one of the big guns like rifampin and others
that we talked about. But no—this is an evolving experience, and
we are making adjustments that are appropriate for managing any
kind of outbreak.
Dr. Daniels:
Dr. Fernando Daniels,
III again. My question is for Dr. Perez, in that we are switching
from doxycycline to cipro and a lot of citizens are worried about
is it as effective as cipro. I would like for you to make a comment
on whether doxycycline is as effective as cipro.
Dr. Perez:
I guess I would
just reiterate what we’ve heard from our Surgeon General to alleviate
those fears as pointed out by Dr. Walks that you go for your big
gun first. As we have all learned, first do no harm. So what we
are doing is we’re going—alleviating that which has the greatest
potential for harm. So we started out with the cipro, the bigger
gun, a broader spectrum, to assure that there would be no resistance,
but we have found that in all of the strands from Florida, New York,
and Washington, all of the strands have been susceptible to doxycycline.
Using doxycycline and using it with the regimen of twice a day is
as effective as using cipro.
Dr. Walter Royal III:
I’m Dr. Walter Royal
III, Department of Medicine at the Neuroscience Institute, Morehouse
School of Medicine. My question is for Dr. Khan. Dr. Khan, could
you tell us what is the case definition for anthrax?
Dr. Khan:
Yes, I can. The
current case definition in the United States for anthrax is divided
into 2 categories, confirmed cases and suspect cases. For confirmed
cases you require clinically compatible illness that is confirmed
by either isolation of Bacillus anthracis or other laboratory
evidence based on 2 supportive laboratory tests: PCR, immunohistochemistry,
or serology. For a suspected case, the definition is clinically
compatible illness with one supportive lab test or a link to an
environmental exposure that we are currently studying.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
<< previous | contents | next >>
- Page last updated November 20, 2002
Get email updates
To receive email updates about this page, enter your email address:
Contact Us:
- Centers for Disease Control and Prevention
1600 Clifton Rd
Atlanta, GA 30333 - 800-CDC-INFO
(800-232-4636)
TTY: (888) 232-6348
24 Hours/Every Day - cdcinfo@cdc.gov